Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Robert Woodford

Pediatrics Omaha, NE Medical Doctor

NPI 1578659991 CMS profile 253444

10060 Regency Cir, Omaha, NE 68114

Open in the dashboard

General payments

$746

46 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Robert Woodford of Omaha, NE is reported in the CMS Open Payments database as having received $746 across 46 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $291 15
2020 General $143 9
2019 General $312 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Woodford
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Robert Woodford were reported at $0. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Robert Woodford Pediatrics median Middle half National median
2019 $312 $86 $31–$183 $163
2020 $143 $49 $22–$110 $114
2021 $0 $68 $27–$158 $132
2022 $291 $77 $30–$173 $149
2023 $0 $88 $33–$190 $160
2024 $0 $94 $34–$206 $164
2025 $0 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Ironshore Pharmaceuticals Inc. $161 11 payments
  2. Tris Pharma Inc $130 7 payments
  3. Pfizer Inc. $93 6 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $66 5 payments
  5. Sanofi Pasteur Inc. $61 3 payments
  6. GlaxoSmithKline, LLC. $41 3 payments
  7. Merck Sharp & Dohme Corporation $37 3 payments
  8. Adlon Therapeutics L.P. $30 2 payments
  9. Neurelis, Inc. $29 1 payment
  10. Supernus Pharmaceuticals, Inc. $23 1 payment
  11. Other $74 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $746 46 payments
Products named General payments · program years 2019–2022
  1. JORNAY PM $108 7 payments
  2. Jornay PM 20mg capsules (Bottle of 100) $54 4 payments
  3. TRUMENBA $49 3 payments
  4. NUCALA $41 3 payments
  5. ROTATEQ $37 3 payments
  6. MENACTRA $36 2 payments
  7. Quillivant XR $35 2 payments
  8. Quillichew ER $32 2 payments
  9. EUCRISA $31 2 payments
  10. ADHANSIA XR $30 2 payments
  11. Other $492 28 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

46 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record